Here, we further investigate the effects of MGAT2 inhibition on 1) fat-induced gut peptide release and fat intake in normal mice and 2) metabolic disorders in high-fat diet (HFD)-fed ob/ob mice, a model of severe obesity and type 2 diabetes mellitus, using an orally bioavailable MGAT2 inhibitor Compound B (CpdB).